Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies

<p>Abstract</p> <p>Background</p> <p>Genomic aberrations can be used to determine cancer diagnosis and prognosis. Clinically relevant novel aberrations can be discovered using high-throughput assays such as Single Nucleotide Polymorphism (SNP) arrays and next-generation...

Full description

Bibliographic Details
Main Authors: Xu Fang, Cheng Elaine, Hoyt Kathleen, Bacchiocchi Antonella, Narayan Deepak, Ariyan Stephan, Parisi Fabio, Li Peining, Halaban Ruth, Kluger Yuval
Format: Article
Language:English
Published: BMC 2011-05-01
Series:BMC Genomics
Subjects:
Online Access:http://www.biomedcentral.com/1471-2164/12/230
_version_ 1823987948125683712
author Xu Fang
Cheng Elaine
Hoyt Kathleen
Bacchiocchi Antonella
Narayan Deepak
Ariyan Stephan
Parisi Fabio
Li Peining
Halaban Ruth
Kluger Yuval
author_facet Xu Fang
Cheng Elaine
Hoyt Kathleen
Bacchiocchi Antonella
Narayan Deepak
Ariyan Stephan
Parisi Fabio
Li Peining
Halaban Ruth
Kluger Yuval
author_sort Xu Fang
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Genomic aberrations can be used to determine cancer diagnosis and prognosis. Clinically relevant novel aberrations can be discovered using high-throughput assays such as Single Nucleotide Polymorphism (SNP) arrays and next-generation sequencing, which typically provide aggregate signals of many cells at once. However, heterogeneity of tumor subclones dramatically complicates the task of detecting aberrations.</p> <p>Results</p> <p>The aggregate signal of a population of subclones can be described as a linear system of equations. We employed a measure of allelic imbalance and total amount of DNA to characterize each locus by the copy number status (gain, loss or neither) of the strongest subclonal component. We designed simulated data to compare our measure to existing approaches and we analyzed SNP-arrays from 30 melanoma samples and transcriptome sequencing (RNA-Seq) from one melanoma sample.</p> <p>We showed that any system describing aggregate subclonal signals is underdetermined, leading to non-unique solutions for the exact copy number profile of subclones. For this reason, our illustrative measure was more robust than existing Hidden Markov Model (HMM) based tools in inferring the aberration status, as indicated by tests on simulated data. This higher robustness contributed in identifying numerous aberrations in several loci of melanoma samples. We validated the heterogeneity and aberration status within single biopsies by fluorescent <it>in situ </it>hybridization of four affected and transcriptionally up-regulated genes E2F8, ETV4, EZH2 and FAM84B in 11 melanoma cell lines. Heterogeneity was further demonstrated in the analysis of allelic imbalance changes along single exons from melanoma RNA-Seq.</p> <p>Conclusions</p> <p>These studies demonstrate how subclonal heterogeneity, prevalent in tumor samples, is reflected in aggregate signals measured by high-throughput techniques. Our proposed approach yields high robustness in detecting copy number alterations using high-throughput technologies and has the potential to identify specific subclonal markers from next-generation sequencing data.</p>
first_indexed 2024-12-18T13:36:04Z
format Article
id doaj.art-cfaf9357a5574aeaa8e8941bdb329d8a
institution Directory Open Access Journal
issn 1471-2164
language English
last_indexed 2024-12-18T13:36:04Z
publishDate 2011-05-01
publisher BMC
record_format Article
series BMC Genomics
spelling doaj.art-cfaf9357a5574aeaa8e8941bdb329d8a2022-12-21T21:06:01ZengBMCBMC Genomics1471-21642011-05-0112123010.1186/1471-2164-12-230Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsiesXu FangCheng ElaineHoyt KathleenBacchiocchi AntonellaNarayan DeepakAriyan StephanParisi FabioLi PeiningHalaban RuthKluger Yuval<p>Abstract</p> <p>Background</p> <p>Genomic aberrations can be used to determine cancer diagnosis and prognosis. Clinically relevant novel aberrations can be discovered using high-throughput assays such as Single Nucleotide Polymorphism (SNP) arrays and next-generation sequencing, which typically provide aggregate signals of many cells at once. However, heterogeneity of tumor subclones dramatically complicates the task of detecting aberrations.</p> <p>Results</p> <p>The aggregate signal of a population of subclones can be described as a linear system of equations. We employed a measure of allelic imbalance and total amount of DNA to characterize each locus by the copy number status (gain, loss or neither) of the strongest subclonal component. We designed simulated data to compare our measure to existing approaches and we analyzed SNP-arrays from 30 melanoma samples and transcriptome sequencing (RNA-Seq) from one melanoma sample.</p> <p>We showed that any system describing aggregate subclonal signals is underdetermined, leading to non-unique solutions for the exact copy number profile of subclones. For this reason, our illustrative measure was more robust than existing Hidden Markov Model (HMM) based tools in inferring the aberration status, as indicated by tests on simulated data. This higher robustness contributed in identifying numerous aberrations in several loci of melanoma samples. We validated the heterogeneity and aberration status within single biopsies by fluorescent <it>in situ </it>hybridization of four affected and transcriptionally up-regulated genes E2F8, ETV4, EZH2 and FAM84B in 11 melanoma cell lines. Heterogeneity was further demonstrated in the analysis of allelic imbalance changes along single exons from melanoma RNA-Seq.</p> <p>Conclusions</p> <p>These studies demonstrate how subclonal heterogeneity, prevalent in tumor samples, is reflected in aggregate signals measured by high-throughput techniques. Our proposed approach yields high robustness in detecting copy number alterations using high-throughput technologies and has the potential to identify specific subclonal markers from next-generation sequencing data.</p>http://www.biomedcentral.com/1471-2164/12/230copy numberSNP arraysNext generation sequencingmelanoma
spellingShingle Xu Fang
Cheng Elaine
Hoyt Kathleen
Bacchiocchi Antonella
Narayan Deepak
Ariyan Stephan
Parisi Fabio
Li Peining
Halaban Ruth
Kluger Yuval
Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies
BMC Genomics
copy number
SNP arrays
Next generation sequencing
melanoma
title Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies
title_full Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies
title_fullStr Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies
title_full_unstemmed Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies
title_short Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies
title_sort detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies
topic copy number
SNP arrays
Next generation sequencing
melanoma
url http://www.biomedcentral.com/1471-2164/12/230
work_keys_str_mv AT xufang detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT chengelaine detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT hoytkathleen detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT bacchiocchiantonella detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT narayandeepak detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT ariyanstephan detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT parisifabio detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT lipeining detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT halabanruth detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies
AT klugeryuval detectingcopynumberstatusanduncoveringsubclonalmarkersinheterogeneoustumorbiopsies